Acta Scientific Paediatrics (ISSN: 2581-883X)

Review Article Volume 3 Issue 4

Potential Armamentarium to Contain COVID-19 Pandemic in Developing Countries: Be Prepared and Act Timely!

CS Gautam1, Roosy Aulakh2* and Priyanka Bhateja3

1Professor and Head, Department of Pharmacology, Government Medical College and Hospital, Chandigarh, India
1Professor, Department of Pediatrics, Government Medical College and Hospital, Chandigarh, India

*Corresponding Author: Roosy Aulakh, Professor, Department of Pediatrics, Government Medical College and Hospital, Chandigarh, India.

Received: March 20, 2020; Published: March 23, 2020



  The world today has a new challenge, the novel coronavirus (2019-nCoV) pandemic which emerged in China in early December 2019 and has brought the entire world to standstill with over 2 lac cases and nearly 9000 deaths reported worldwide. As the virus has been demonstrated to have high transmissibility with humans worldwide lacking immunity, an exponential rise in cases is expected in countries where initial cases have just emerged. Though researchers have documented efficacy of anti-viral drugs like Remdesivir/Lopinavir/Ritonavir/Ribavarin in treating cases of pneumonia caused by COVID-19 [1], these drugs are neither easily available nor is it financially feasible to use these drugs in developing countries like India.

Keywords: Novel Coronavirus (2019-nCoV); Pandemic; Anti-Viral Drugs; Armamentarium



  1. Lim J., et al. “Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR”. Journal of Korean Medical Science 35.6 (2020): e79. 
  2. Pasquier B. “Autophagy inhibitors”. Cellular and Molecular Life Sciences 73.5 (2016): 985-1001. 
  3. Slater AF. “Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum”. Pharmacology and Therapeutics 57.2-3 (1993): 203-235.
  4. Vincent MJ., et al. “Chloroquine is a potent inhibitor of SARS coronavirus infection and spread”. Virology Journal 2 (2005): 69.
  5. Gao J., et al. “Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies”. BioScience Trends 14.1 (2020): 72-73. 
  6. “Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia (Chinese)”. Zhonghua Jie He He Hu Xi Za Zhi 43.3 (2020): 185-188. 
  7. Xue J., et al. “Chloroquine Is a Zinc Ionophore”. PLOS One 9.10 (2014): e109180.
  8. Liu J., et al. “Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro”. Cell Discovery 6 (2020): 16. 
  9. Cortegiani A., et al. “A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19”. Journal of Critical Care (2020).
  10. Interim clinical guidance for patients suspected of/confirmed with COVID-19 in Belgium. Version 3 (2020). 
  11. Savarino A., et al. “New insights into the antiviral effects of chloroquine”. Lancet Infectious Diseases 6.2 (2006): 67-69.
  12. Takeda K., et al. "Toll-Like Receptors". Annual Review of Immunology 21 (2003): 335-376. 
  13. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395.10223 (2020): 497-506.
  14. Prasad AS. “Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health”. Frontiers in Nutrition 1 (2014): 14. 
  15. Awotiwon AA., et al. “Zinc supplementation for the treatment of measles in children”. Cochrane Database of Systematic Reviews 6 (2017): CD011177.
  16. Velthuis AJW., et al. “Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture”. PLOS Pathogens 6.11 (2010): e1001176. 
  17. Zhang L and Liu Y. “Potential interventions for novel coronavirus in China: A systematic review”. Journal of Medical Virology 92.5 (2020): 479-490.
  18. Ikemoto K., et al. “Contribution of anti-inflammatory and anti-virulence effects of azithromycin in the treatment of experimental Staphylococcus aureus keratitis”. BMC Ophthalmology 20.1 (2020): 89. 
  19. Kuo CH., et al. “Azithromycin suppresses Th1- and Th2-related chemokines IP-10/MDC in human monocytic cell line”. Journal of Microbiology, Immunology and Infection 52.6 (2019): 872-879. 
  20. Gautret., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial”. International Journal of Antimicrobial Agents (2020).
  21. Kampf G., et al. “Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents”. Journal of Hospital Infection 104.3 (2020): 246-251. 
  22. Rossignol JF. "Nitazoxanide: a first-in-class broad-spectrum antiviral agent". Antiviral Research 110 (2014): 94-103. 
  23. Keil SD., et al. “Inactivation of Middle East respiratory syndrome coronavirus (MERS‐CoV) in plasma products using ariboflavin‐based and ultraviolet light‐based photochemical treatment”. Transfusion 56.12 (2016): 2948‐2952.


Citation: CS Gautam and Roosy Aulakh. “Potential Armamentarium to Contain COVID-19 Pandemic in Developing Countries: Be Prepared and Act Timely!" Acta Scientific Paediatrics 3.4 (2020): 39-42.

Member In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for March Issue
    The last date for submission of articles for regular Issues is April 10, 2020.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US